Point72 Asia Singapore Pte. Ltd. Makes New $92,000 Investment in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 127,634 shares of the biotechnology company’s stock, valued at approximately $92,000.

A number of other hedge funds have also modified their holdings of MCRB. Mirae Asset Global Investments Co. Ltd. purchased a new position in Seres Therapeutics in the first quarter valued at about $39,000. Providence Wealth Advisors LLC grew its stake in shares of Seres Therapeutics by 49.5% in the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 25,250 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Seres Therapeutics in the second quarter worth approximately $64,000. Virtu Financial LLC bought a new position in Seres Therapeutics during the first quarter valued at approximately $73,000. Finally, Pennant Investors LP acquired a new stake in Seres Therapeutics in the fourth quarter valued at approximately $409,000. 59.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MCRB has been the topic of several analyst reports. Chardan Capital restated a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research note on Wednesday, August 14th. StockNews.com cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. Oppenheimer reiterated a “market perform” rating on shares of Seres Therapeutics in a research note on Friday, June 7th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research note on Friday, September 13th.

Seres Therapeutics Price Performance

MCRB stock opened at $0.85 on Friday. The stock has a market capitalization of $128.50 million, a price-to-earnings ratio of -1.41 and a beta of 2.03. The company has a 50-day moving average of $0.97 and a two-hundred day moving average of $0.91. Seres Therapeutics, Inc. has a 52-week low of $0.54 and a 52-week high of $2.11.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. During the same period last year, the business posted $0.36 earnings per share. Equities analysts expect that Seres Therapeutics, Inc. will post -0.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Seres Therapeutics news, insider Teresa L. Young sold 24,480 shares of the firm’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $1.08, for a total value of $26,438.40. Following the sale, the insider now directly owns 78,178 shares in the company, valued at $84,432.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 28,844 shares of company stock valued at $30,104. 5.10% of the stock is owned by company insiders.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.